Results 81 to 90 of about 1,772,484 (313)

Presence and persistence of Ebola or Marburg virus in patients and survivors: A rapid systematic review [PDF]

open access: yes, 2016
Background: The 2013-15 Ebola outbreak was unprecedented due to sustainedtransmission within urban environments and thousands of survivors. In 2014 the World Health Organization stated that there was insufficient evidence to give definitive guidance ...
Brainard, Julii   +4 more
core   +3 more sources

Inhibition of the clathrin terminal domain – amphiphysin protein‐protein interaction. Probing the Pitstop® 2 aromatic moiety.

open access: yesChemMedChem, Accepted Article.
Pitstop 2, (Z)‐N‐(5‐(4‐bromenzylidene)‐4‐oxo‐4,5‐dihydrothiazol‐2‐yl)naphthalene‐1‐sulfonamide (1), inhibits the clathrin terminal domain‐ amphiphysin interaction (NTD‐PPI) and has been widely used to investigate endocytosis. In this work we report on the synthesis of 56 novel Pitstop 2 analogues via four discrete focused libraries.
Kate Prichard   +10 more
wiley   +1 more source

A genome-wide CRISPR screen identifies N-acetylglucosamine-1-phosphate transferase as a potential antiviral target for Ebola virus

open access: yesNature Communications, 2019
There are no approved therapies for Ebola virus infection. Here, to find potential therapeutic targets, we perform a screen for genes essential for Ebola virus (EBOV) infection.
M. Flint   +10 more
semanticscholar   +1 more source

Ebola Virus Diseases

open access: yesAfrican Journal of Clinical and Experimental Microbiology, 2014
Since the first reported outbreak of Ebola in 1976, there have been approximately 25 outbreaks all of which, except two, have been reported only in east and central Africa. The current outbreak and a single case reported in 1994 in Ivory Coast are the only two outbreaks in West Africa (7).
A Elisha, B Adegboro
openaire   +4 more sources

Delayed Disease in Cynomolgus Macaques Exposed to Ebola Virus by an Intranasal Route

open access: yesFrontiers in Immunology, 2021
Ebola virus remains a significant public health concern due to high morbidity and mortality rates during recurrent outbreaks in endemic areas. Therefore, the development of countermeasures against Ebola virus remains a high priority, and requires the ...
Sara C. Johnston   +6 more
doaj   +1 more source

Ebola virus disease epidemic in West Africa: Lessons learned and issues arising from West African countries [PDF]

open access: yes, 2015
© Royal College of Physicians 2015. All rights reserved.The current Ebola virus disease (EVD) outbreak ravaging three nations in West Africa has affected more than 14,000 persons and killed over 5,000.
Akpalu, AK   +6 more
core   +1 more source

Populations Addressed in Vaccines Approved via the European Medicines Agency

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Therapeutic and prophylactic agents require robust evidence before patient use. Randomized controlled trials are essential for evaluating safety and efficacy but often exclude specific populations that are also targets for the intervention. This study assessed which populations are included in vaccine registration studies and/or addressed in label ...
Débora D. Gräf   +3 more
wiley   +1 more source

Cutaneous manifestations of the ebola virus [PDF]

open access: yesDermatology Online Journal, 2015
The current Ebola outbreak has drawn attention to the virus in the medical community. Zaire ebolavirus, more commonly known as 'the Ebola virus,' is a level 4-security agent in the Filoviridae family. The main cutaneous finding of Ebola is a nonspecific maculopapular rash that appears between day four and six of disease.
Blattner, Collin M   +2 more
openaire   +5 more sources

Unusual Ebola Virus Chain of Transmission, Conakry, Guinea, 2014–2015

open access: yesEmerging Infectious Diseases, 2016
In October 2015, a new case of Ebola virus disease in Guinea was detected. Case investigation, serology, and whole-genome sequencing indicated possible transmission of the virus from an Ebola virus disease survivor to another person and then to the case ...
Mory Keita   +12 more
doaj   +1 more source

Identification of Novel Adjuvants for Ebola Virus-Like Particle Vaccine

open access: yesVaccines, 2020
Ebola virus disease is a severe disease, often fatal, with a mortality rate of up to 90%. Presently, effective treatment and safe prevention options for Ebola virus disease are not available. Therefore, there is an urgent need to develop control measures
Huapeng Feng   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy